Regenerative Medicine and Cell Therapies Virtual Event, page-103

After listening to the presentations at the Alliance for Cell Therapy Now, we learned that Mesoblast has scaled production to meet the SRaGVHD market and some of the COVID ARDS market. We are also reminded that this is expensive to manufacture – so remestemcel-l price should reflect that.
While a volume for GVHD was not shared, they stated that they will have inventory to treat 10,000 with COVID ARDS over 6 months (glad to see this vote of confidence! aligns with the recent capital raise).
From this one can explore the revenue outlook:
If, given the expense, charge $20K per dose….
If 6,000 GVHD cases (8 doses)
If 20,000 COVID ARDS per year (2 doses)
This would be $1.76B in revenue over 12 months out of the gate, with huge growth opportunities (yes plural) in front of Mesoblast.
Market capitalization is normally a multiple of revenue, based on growth outlook, so pick your multiple to reflect this opportunity.
Market capitalization is only $2.1B. Lots of room to run.
Unlike companies which over promise and under deliver (aka CYDY), Mesoblast quietly works to delivers results.